1,721,118 research outputs found
Impiego di un'associazione cofosfolattamina precostituita (fosfomicina + amoxicillina) nell'insufficienza renale
No full textThe rationale for a preformed combination of fosfomycin and amoxicillin is briefly discussed. These two antibacterial drugs block the peptidoglycal biosynthesis sequentially, thus exerting a true synergistic effect. On the other hand, there is no no synergism as far as toxicity is concerned. As the kinetics of the two molecules are different, further research on this topic is needed. This is especially true for renal failure patient
Human cytomegalovirus DNAemia and preemptive treatment of CMV infection in children after hematopoietic stem-cell transplantation: is any question settled?
No full textComments on a prospective trial on the use of CMV DNAemai for the early diagnosis of CMV infectio
Lymphocyte transformation response to B-specific mitogens and its correlation with delayed hypersensitivity in HIV-infected patients
No full textImmune response to Hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis
No full textIt is debated whether patients with celiac disease (CD) have non-protective antibody responses to HBV vaccination more frequently than non-affected subjects. To perform a literature review and meta-analysis on protective response to HBV vaccination in CD patients. RCTs and observational controlled studies were eligible. Outcome of interest was an anti-HBs (HBsAb) titer ≥10 IU/L after last vaccine dose. Comparative index was rate ratio (RR). Heterogeneity between studies was addressed and funnel plots were analyzed. Meta-regression models were applied to investigate effect size due to study-specific variables. Twelve retrospective studies on a total of 1,447 participants and 4 prospective studies on 184 subjects were selected. The RR was 0.732 (95% C.I.: 0.664-0.808) and 0.777 (95% C.I.: 0.629-0.960) in the prospective and retrospective studies, respectively. The I(2), indicating heterogeneity, was 51.1% in retrospective, 39.8% in prospective studies. Non-protective antibody responses occurred more frequently in patients than controls. Due to limitations in the available studies, additional trials to evaluate post-vaccination HBsAb titer in CD patients are needed
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
No full textBackground: Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality among haemophilic patients who were treated with clotting factor concentrates before the availability of virus-inactivated factors in the mid 1980s. In order to analyse the effect of the current combination anti-HCV treatment [i.e. ribavirin plus interferon (IFN)] in this subset of HCV-infected patients, we performed a systematic review with meta-analysis of the available literature. Methods: The outcome was sustained viral suppression. When trials included for the main predictors two arms (positive and negative), the effect size was described as a comparative index [odds ratio (OR)] and a standard meta-analytical procedure was applied. However, when trials did not report the outcome in separate study arms, the effect size was a non-comparative index (success rate) and comparisons between predictor-positive and -negative studies were performed by meta-regression. Results: Data involving 824 haemophilic HCV-infected patients treated with IFN plus ribavirin were collected from 18 articles (14 prospective cohort studies, 1 retrospective study and 3 randomized controlled trials). The higher rate of sustained viral response was observed in human immunodeficiency virus (HIV)-negative naive haemophiliacs treated with pegylated-IFN in combination with ribavirin (61%, ranging from 45% for genotype 1 to 79% for non-1 genotypes). Genotype 1 (OR, 0.15; 95% CI, 0.09-0.25) and co-infection with HIV (OR, 0.25; 95% CI, 0.08-0.81) were strong predictors of worse response to IFN therapy. Conclusions: Our meta-analysis shows that the pattern of response to combination anti-HCV therapy of chronically HCV-infected haemophiliacs is similar to that achieved in the general HCV-infected population. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved
Celiac disease in adult patients
No full textCeliac disease (CD) may affect individuals of any age and sex and may present with various clinical presentations. Specifically, CD has proteiform manifestations, spacing from a totally asymptomatic presentation (silent CD) to few or mild signs or symptoms, such as isolated anemia, osteoporosis, vague or unspecific gastrointestinal symptoms (subclinical CD), and to a frank malabsorption syndrome, including steatorrhea, weight loss, electrolyte imbalance, hypoalbuminemia. Additionally, different extraintestinal manifestations may accompany CD, such as dermatitis herpetiformis, other skin/oral diseases, neuropsychiatric alterations, and liver function test abnormalities. In this Chapter, we will discuss the possible clinical manifestations of CD in adults, also including specific populations (e.g., the elderly, patients with other autoimmunity), how to follow-up CD patients, the mortality related to CD, and the impact of the recent Covid-19 pandemic on CD patients
- …
